Analysts expect Allarity Therapeutics, Inc. to report revenue of 0.00 for Q3 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | 0.00 | 0.00 | 0.00 | 320,000.00 | 25,000.00 | 0.00 | - | - | - | - | - | - | ||||
| High Estimate | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47,678.33 | ||||
| Low Estimate | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40,908.77 | ||||
| Consensus Estimate | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44,293.55 |
Analysts expect Allarity Therapeutics, Inc. to report earnings per share of -7.66 for Q4 24, against a range of -8.12 to -7.20. The most recent reported quarter, Q2 26, came in at -0.21, a 12.5% beat against the -0.24 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -7.71 | - | -0.25 | -0.15 | -0.19 | -0.19 | -0.17 | -0.21 | - | - | - | - | - | - | - | |||
| High Estimate | -8.10 | -7.20 | - | -0.21 | -0.21 | -0.20 | -0.20 | -0.23 | -0.23 | -0.24 | -0.24 | -0.22 | 0.60 | 0.79 | 1.25 | |||
| Low Estimate | -9.24 | -8.12 | - | -0.23 | -0.23 | -0.22 | -0.22 | -0.25 | -0.25 | -0.28 | -0.30 | -0.24 | 0.50 | 0.75 | 1.15 | |||
| Consensus Estimate | -8.67 | -7.66 | - | -0.22 | -0.22 | -0.21 | -0.21 | -0.24 | -0.24 | -0.26 | -0.27 | -0.23 | 0.55 | 0.77 | 1.20 |